Incretin and Insulin Signaling as Novel Therapeutic Targets for Alzheimer’s and Parkinson’s Disease

Incretin and insulin signaling as novel therapeutic targets for Alzheimer’s and Parkinson’s disease

Despite an ever-growing prevalence and increasing economic burden of Alzheimer’s disease (AD) and Parkinson’s disease (PD), recent advances in drug development have only resulted in minimally effective treatment. In AD, along with amyloid and tau phosphorylation, there is an associated increase in inflammation/glial activation, a decrease in synaptic function, an increase in astrocyte activation, and a state of insulin resistance. In PD, along w…

Japanese lab in final phase testing Parkinson’s drug for Alzheimer’s disease

New study tests Parkinson’s drug to treat early-onset familial Alzheimer’s disease, a rare form of dementia, with results expected by 2028 - Anadolu Ajansı